When was LAPIX founded?

LAPIX was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is LAPIX located?

LAPIX is headquartered in Boston, United States.

Who is the current CEO of LAPIX?

Anas Fathallah of LAPIX. They have also founded 1 company.

How many employees does LAPIX have?

As of Jun 30, 2026, the latest employee count at LAPIX is 13.

Is LAPIX a funded company?

LAPIX is a funded company, having raised a total of $8.97M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 18, 2022.

When was the latest funding round of LAPIX?

LAPIX's latest funding was a $***** Series A round on Jul 21, 2025, with participation from 0 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $3B in funding in 2026 to date.

Where does LAPIX rank among its competitors?

LAPIX ranks 1205th amongst 3708 active competitors, of which 1258 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of LAPIX?

LAPIX's top competitors include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Among them, Senti Bio secured the most recent funding round in May, 2026.

LAPIX - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immunotherapies for immunological diseases. It offers a lead candidate LPX-TI641 for multiple sclerosis, Neuromyelitis Optica, Rheumatology, LPX-TIIBD for Inflammatory bowel disease, and also provides gene therapy.

Website: lapix.com
Social

Key Metrics

Founded Year

2019

Location

Boston, United States

Stage

Series A

Total Funding

$8.97M in 3 rounds

Latest Funding Round

Series A, Jul 21, 2025, $*****

Ranked

1205^th among 3708 active competitors

Employee Count

13 as on Jun 30, 2026

Similar Companies

Biogen & 1230 more

View LAPIX's full profile

LAPIX is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Lapix Therapeutics Inc. CIN: 842410144 , United States, Active		-	-	-

LAPIX has raised a total funding of $8.97M over 3 rounds. Its first funding round was on Oct 18, 2022.

Here is the list of recent funding rounds of LAPIX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 21, 2025	1808333	Series A	4993471	2859642	3774932	5518754
Aug 02, 2024	3593317	Series A	9943695	7269174	7561520	8190163
Oct 18, 2022	5299965	Seed	4521444	6247400	3634987	4138459

Access funding benchmarks and valuations. Sign up today!

View details of LAPIX's funding rounds and investors

The founders of LAPIX are Jason Norris and Anas Fathallah. Anas Fathallah is the CEO of LAPIX.

Here are the details of LAPIX's key team members:

Jason Norris: Co-Founder of LAPIX and founder of 2 other companies, Elektrofi and Mytide.
Contact Info: 1 email address
Anas Fathallah: Co-Founder & CEO of LAPIX and founder of 1 other company.
Contact Info: 1 email address

View details of LAPIX's Founder profiles and Board Members

LAPIX's employee count trend

LAPIX has 13 employees as of Jun 26. Here is LAPIX's employee count trend over the years:

Uncover LAPIX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LAPIX include Jazz Pharmaceuticals, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of LAPIX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
1205th	LAPIX 2019, Boston (United States), Series A	Developer of immunotherapies for immunological diseases	$8.97M	-	40/100